Webinar Five
Release Date: July 1, 2020, Expiration Date: June 30, 2022
Learning Objectives:
- Participants will be able to describe immunotherapies for GBM.
- Participants will be able to understand which immunotherapies have been tested in patients with GBM.
- Participants will be able to describe how immunomodulation can be leveraged in the treatment of GBM.
Target Audience:
This lecture is attended for primary care physicians, specialty physicians, physician assistants and nurses.
Accreditation:
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit:
The University of Florida College of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME Planning Committee Disclosure:
Conflict of interest information for the CME Advisory Committee members can be found on the following website: https://cme.ufl.edu/disclosure/.
Faculty Disclosure:
Dr. Rahman has disclosed that she has no relevant financial disclosures. No one else in a position to control content has any financial relationships to disclose.
Bibliographic Sources:
Weller, M., Butowski, N., Tran, D. D., Recht, L. D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., Goldlust, S. A., Iwamoto, F., Drappatz, J., O’Rourke, D. M., Wong, M., Hamilton, M. G., Finocchiaro, G., Perry, J., Wick, W., Green, J., He, Y., Turner, C. D., … ACT IV trial investigators (2017). Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. The Lancet. Oncology, 18(10), 1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X
Dastmalchi, F., Karachi, A., Yang, C. et al. Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling. j. immunotherapy cancer 7, 321 (2019). https://doi.org/10.1186/s40425-019-0809-4
Back to CME Series Main Page